Greg Madison of Shield Therapeutics: “There is a very substantial market opportunity for Accrufer®”

Greg Madison CEO of Shield Therapeutics #STX discusses their strong Q2 which showed total prescriptions for Accrufer® increase by 50% compared to Q1 and says, “There is a very substantial market opportunity for Accrufer® and we are looking to identify ways to maximise the momentum we are building in order to further drive continued Accrufer® growth”

Read full RNS here: